LDN-212854
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-15897-5MG | 5 mg | 168,00 | Add | |
| HY-15897-1ML | 10mM/1mL | 183,00 | Add | |
| HY-15897-10MG | 10 mg | 299,00 | Add | |
| HY-15897-25MG | 25 mg | 584,00 | Add | |
| HY-15897-50MG | 50 mg | 1'040,00 | Add | |
| HY-15897-100MG | 100 mg | 1'534,00 | Add | |
| HY-15897-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC)[1][2].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, TGF-beta/Smad |
| Format | Solubility: DMSO : ≥ 30 mg/mL |
| Grade | Clinical information: No Development Reported |
| Purity | 99.7% |
| Molecular Formula | C25H22N6 |
| Molecular Weight | 406.48 |
| CAS-Number | 1432597-26-6 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
